Phaseline

Targets › TRPV1

TRPV1 (Transient receptor potential cation channel subfamily V member 1): drug programs, companies and trials

11 programs from 9 companies in 16 trials: 7 Phase 2, 4 Phase 3, 3 Phase 4, 2 Phase 1; Neurology, Other, Psychiatry; next expected readout Dec 2026.

Non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. (UniProt, Q8NER1)

Open in Phaseline: the race on TRPV1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, Clermont-FerrandCapsaicin
Vanilloid receptor opener
TRPV1Phase 4Osteoarthritis HandJan 2028
Heron TherapeuticsHTX-011
Fixed-ratio combination of bupivacaine and meloxicam; bupivacaine is a local anesthetic th
TRPV1Phase 4Analgesia–
Valenta Pharm JSC4-MUST (trimebutine 4-methylumbelliferyl sulfate)
Trimebutine derivative; prokinetic agent acting as TRPV1 agonist and 5-HT4 receptor agonis
TRPV1, HTR4Phase 3Chronic CholecystitisDec 2026
Nantes University HospitalCapsaicin
Vanilloid receptor opener
TRPV1Phase 3Coccyx DisorderMay 2027
Institut Cancerologie de l'OuestCapsaicin
Vanilloid receptor opener
TRPV1Phase 3Chemotherapy-induced Peripheral NeuropathyMar 2028
University Hospital, BrestCapsaicin
Vanilloid receptor opener
TRPV1Phase 3Neuropathic PainJul 2028
RDC ClinicalOleoylethanolamide (Trpti)
Endocannabinoid-like compound; TRPV1 and PPAR-alpha agonist with appetite regulation and s
TRPV1, PPARAPhase 2Sleep Disorder (Disorder); Healthy VolunteersFeb 2027
RDC ClinicalPalmitoylethanolamide (PEA)
Endocannabinoid-like lipid signaling molecule; acts as agonist at TRPV1 and PPARα receptor
TRPV1, PPARAPhase 2Sleep Disorder (Disorder); Healthy; Persistent Postural Perceptual DizzinessFeb 2027
Instituto Mexicano del Seguro SocialCapsaicin
Vanilloid receptor opener
TRPV1Phase 2Ischemic Stroke–
RDC ClinicalLevagen+ (palmitoylethanolamide, PEA)
Lipid signaling molecule; TRPV1 antagonist and PPARδ agonist with anti-inflammatory and ne
TRPV1, PPARDPhase 2Diabetic Peripheral Neuropathy–
Universiti Kebangsaan Malaysia Medical CentreLignocaine-loaded maltose microneedle array patch
Local anesthetic delivered via biodegradable maltose microneedle array for enhanced transd
TRPV1Phase 1GlaucomaDec 2026

Conditions

Chronic Cholecystitis (3) Sleep Disorder (Disorder) (2) Neuropathic Pain (1) Chemotherapy-induced Peripheral Neuropathy (1) Glaucoma (1) Osteoarthritis Hand (1) Coccyx Disorder (1) Analgesia (1) Ischemic Stroke (1) Healthy (1) Persistent Postural Perceptual Dizziness (1) Healthy Volunteers (1)

Modalities

small molecule (8)

Companies

RDC Clinical (3) University Hospital, Brest (1) Institut Cancerologie de l'Ouest (1) Universiti Kebangsaan Malaysia Medical Centre (1) University Hospital, Clermont-Ferrand (1) Nantes University Hospital (1) Valenta Pharm JSC (1) Heron Therapeutics (1) Instituto Mexicano del Seguro Social (1)

Related targets

PPARA (2) HTR4 (1) PPARD (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.